Digital healthcare company Wellysis has partnered with Artella Solutions to launch a remote cardiac monitoring service in the US. 

The partnership builds on Wellysis' US Food and Drug Administration (FDA)-cleared S-Patch electrocardiogram monitoring system, now enhanced with the S-Patch ExL device. 

Wellysis said that this S-Patch ExL model enables for prolonged monitoring periods of up to 14 days on a single coin battery. It received FDA approval earlier this year. 

The S-Patch ExL device enables Wellysis, a spin-off from Samsung, to broaden its services in the Extended Holter and Mobile Cardiac Telemetry (MCT) sectors.  

The partnership with ARTELLA will facilitate the provision of an end-to-end cardiac monitoring service, initially launching in Texas.  

Wellysis CEO Young Juhn said: “We are thrilled to partner with ARTELLA for our remote cardiac monitoring service in the US, introducing this end-to-end solution using S-Patch to US patients. This collaboration signifies the beginning of an exciting journey, with plans to integrate AI algorithms soon.” 

Currently operating across ten states in the US, ARTELLA offers a comprehensive solution for remote cardiac monitoring. 

ARTELLA co-founder and CEO Sepand Moshiri said: “This organic journey has led to a dynamic partnership with Wellysis, combining forces to redefine the future of patient care. Together, we are at the forefront of cardiac monitoring innovation, harnessing the power of artificial intelligence and virtual real-time monitoring." 

The service package includes the integration of Samsung smartphones and smartwatches with the S-Patch ExL device, creating a seamless user experience for patients.  

Last year, Wellysis received FDA approval to market its wearable electrocardiography (ECG) patch, S-Patch Ex.  

At that time, the company stated that this product was being exported to 14 countries, including UK, Spain, Italy, Greece, Poland, Australia, Thailand, India, and Korea.